跳转到主要内容
首页

Dedicated to discovery

  • 关于 ELGA
    • 关于 ELGA
    • 招贤纳士
    • 活动
  • 支持
    • 实验室规划
    • 注册产品
    • Register Your Product (USA & Canada Only)
  • 联系信息
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 日本
首页
  • 产品
    • PURELAB
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 2 +
      • PURELAB® Chorus 3
      • PURELAB® flex 1
      • PURELAB® flex 2
      • PURELAB® flex 3
      • PURELAB® flex 4
      • PURELAB® flex 5
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY 30
    • ELGA 全产品系列
  • 应用
    • 一般实验室用水要求
    • 临床生物化学
    • 免疫化学
    • 分光光度测定法:
    • 原子光谱分析法
    • 微生物分析
    • 气相色谱分析法
    • 液相色谱
    • 电化学
    • 细胞培养
    • 质谱分析法
    • 遗传学
  • 水纯化技术
    • PureSure
    • 反渗透法
    • 活性碳
    • 电去离子法
    • 离子交换法
    • 紫外线照射法
    • 过滤
  • 水中杂质
    • 微生物和细菌
    • 微粒
    • 无机化合物
    • 有机化合物
    • 溶解气体
  • 知识
    • 博客
    • 案例分析
    • 超纯水
    • 白皮书
  • 认证合作伙伴
  • 联系信息
Home
  • 联系信息
  • 产品
    • PURELAB
      • PURELAB® Quest
      • PURELAB® Pharma Compliance
      • PURELAB® Chorus 1 Complete
      • PURELAB® Chorus 1
      • PURELAB® Chorus 2
      • PURELAB® Chorus 2 +
      • PURELAB® Chorus 3
      • PURELAB® flex 1
      • PURELAB® flex 2
      • PURELAB® flex 3
      • PURELAB® flex 4
      • PURELAB® flex 5
    • CENTRA
      • CENTRA® R60/120
      • CENTRA® R200
      • CENTRA® RDS
    • MEDICA
      • MEDICA® 7/15
      • MEDICA® Pro-R & Pro-RE
      • MEDICA® R200
      • MEDICA® EDI 15/30
      • MEDICA® Pro-LPS
      • MEDICA® Pro EDI 60/120
      • MEDICA® BIOX
      • Hubgrade
    • BIOPURE
      • BIOPURE® 300/600
    • PURENERGY 30
    • ELGA 全产品系列
  • 应用
    • 一般实验室用水要求
    • 临床生物化学
    • 免疫化学
    • 分光光度测定法:
    • 原子光谱分析法
    • 微生物分析
    • 气相色谱分析法
    • 液相色谱
    • 电化学
    • 细胞培养
    • 质谱分析法
    • 遗传学
  • 水纯化技术
    • PureSure
    • 反渗透法
    • 活性碳
    • 电去离子法
    • 离子交换法
    • 紫外线照射法
    • 过滤
  • 水中杂质
    • 微生物和细菌
    • 微粒
    • 无机化合物
    • 有机化合物
    • 溶解气体
  • 知识
    • 博客
    • 案例分析
    • 超纯水
    • 白皮书
  • 认证合作伙伴
  • 联系信息
  • 关于 ELGA
    • 关于 ELGA
    • 招贤纳士
    • 活动
  • 支持
    • 实验室规划
    • 注册产品
    • Register Your Product (USA & Canada Only)
  • 联系信息
  • U.S.A.
  • U.K.
  • Deutschland
  • España
  • France
  • Italia
  • Brasil
  • 日本
  • 隐私政策
  • 条款和条件
  • 全球法律合规
  • 专利
  • Trademarks
  • 页面操作员
  • 首页
  • What’s the Future of Pharma?
Clinical & Pharma
Science of the Future

What’s the Future of Pharma?

25 1月 2020
- by ELGA Editorial Team

Medicine doctor and stethoscope touching icon heart and diagnostics analysis medical on modern virtual screen interface network connection. Medical technology diagnostics of heart concept

The pharmaceutical industry has been in a very specific transition in the last decade: new business models, regulatory changes (e.g. cold WFI), challenges in the German healthcare system (e.g. an aging population) and a growing demand for pharmaceutical products in emerging markets determined the direction . Where is the industry headed now and how will the pharmaceutical industry use laboratory water – probably its most important resource – effectively in the future?


A changing landscape

A decline in the traditional small molecule drug development pipeline and fierce generic competition mean the era of “blockbuster” drugs may be over. To remain financially sustainable, many companies have shifted their focus to new, large-molecule biologic drugs. In 2008, biopharmaceuticals accounted for just 16% of pharmaceutical sales. In 2019 it was already 27.4%.

Novel biological therapeutics bring with them a number of additional manufacturing challenges. They are more prone to contamination in the production process than traditional small molecule drugs, and manufacturers need to ensure that production conditions are carefully controlled. For example, the production of biologics based on monoclonal antibodies requires a significant amount of  ultrapure water for cell culture  and downstream processing.

Other up-and-coming areas such as nanomedicine and stem cell treatments also pose special challenges in terms of ensuring production quality. Regenerative medicines, for example, are based on tissue samples from the patient and therefore many of the preparation steps have to be carried out in closed systems at the "point of care". The establishment of compact, sterile production facilities will be essential to ensure the highest level of patient safety and treatment efficiency.

Regulatory processes influence market launch

Regulatory approval processes will also evolve as new methods of evaluating, approving and monitoring the safety and efficacy of these medicines emerge. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are now placing a much greater focus on post-market surveillance to ensure patient safety. EMA, for example, recently ran a pilot program for ' adaptive approval ', in which new therapies are approved on the basis of further testing to confirm their safety and effectiveness in different patient populations.

For the pharmaceutical industry, this means that traditional approaches to launching products are likely to give way to a phased approach, where demand for a product increases as a license is renewed. However, as the time lag between a product's launch and peak sales increases, so does the time it takes to recoup spending on manufacturing infrastructure. Therefore, rather than investing conventionally in a manufacturing facility designed to meet maximum demand from day one, a company bringing a new drug to market will increasingly need a flexible supply chain that can quickly adjust as approval changes changes.

In order to be able to cope with these shifts in demand, manufacturers must also provide an infrastructure that can be easily expanded. For example, traditional scale-up approaches could be replaced by "numbering-up," where additional micromodules are simply added as needed. Modular systems for the production of laboratory water  for pharmaceutical companies that can use this "Lego-like" structure of micro-reaction technology then offer advantages over fixed systems.

Growing environmental pressure also for pharmaceutical companies

Of course, the pharmaceutical sector is not immune to global developments in the sustainability and eco-friendliness issues facing the industry in general, particularly when it comes to water consumption. The UN predicts that by 2025, 1.8 billion people will be living in regions of severe water stress, while 5 billion will be living in "water stress" conditions. This problem will acutely affect parts of China, India and sub-Saharan Africa. Germany will have to face this phenomenon more and more frequently in phases.

As the pharmaceutical industry is a large consumer of water, this issue will increasingly influence decisions about the siting of production facilities and the use of resource-efficient systems. This will mainly, but not only, affect regions in emerging markets. For sustainable growth, the pharmaceutical industry must ensure that it uses the best possible solutions throughout the drug development process to minimize its water footprint. Energy-efficient systems that use resources intelligently, e.g. Devices such as those that can control the flow rate depending on the application will play an important role in overcoming these challenges.

Conclusion

As the pharmaceutical industry evolves to meet tomorrow's healthcare needs, it is clear that water purification and laboratory water production will play a crucial role. Increasingly efficient and flexible purification systems will be essential to provide the ultrapure water needed for the sustainable production of innovative therapies. By working with technology providers like Veolia's ELGA Labwater, the industry can continue to provide safe and effective treatments to those who need them.

 

Quest Download

PURELAB Quest

The only purifier on the market that dispenses all 3 types of science ready water from a compact, economical and easy to use system!

             Click Here To Find Out More

 

  • Enquiry
  • 获取报价
  • 预订演示
  • 联系获认证的合作伙伴

Enquiry

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

获取报价

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

预订演示

At ELGA LabWater, we have exciting offers and news about our products and services that we hope you’d like to hear about. We will use your information to predict what you might be interested in. We will treat your data with respect and you can find the details in our Privacy Policy.

ELGA LabWater works with a network of Approved Partners. In order to answer your questions or enquiries, we may pass your contact details to an Approved Partner, who may contact you directly. 

I'd like to receive updates from ELGA LabWater & ELGA Approved Partners based on my details.

Call us

Can't find what you are looking for?

Support Number
+44 (0)20 3567 7300
United Kingdom Sales
+44 (0)1628 879 704
United States of America Sales
+1 877-315-3542
France Sales
+33 1 40 83 65 00
China Sales
+86 400-616-8882

 

ELGA LabWater US Headquarters

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
电话: +44 (0) 203 567 7300
传真:+44 (0) 203 567 7205

Elga LabWater 总部

Lane End Business Park
Lane End, High Wycombe
HP14 3BY
United Kingdom
电话: +44 (0) 203 567 7300
传真:+44 (0) 203 567 7205

案例研究

  • 雅培诊断
  • DASA 医学诊断
  • NeoDIN 医学研究所
  • 北斯塔福德郡 NHS 信托大学医院
  • Olsberg 职业技术学院

资源

  • 了解超纯水
  • 白皮书
  • 水纯化技术
  • 实验室应用
  • 水中杂质

Blogs

  • Latest Blog
  • Water Purity - Different Types of Pure Water
  • What is Clinical Laboratory Reagent Water (CLSI)?
  • What is Total Organic Carbon (TOC)?

© VWS (UK) Ltd. 以 ELGA®LabWater 的名义经营业务。2023- 保留所有权利
ELGA 是 Veolia 旗下全球实验室用水品牌。

  • 隐私政策
  • 条款和条件
  • 全球法律合规
  • 专利
  • Trademarks
  • 页面操作员
  • 语言
    • Deutsch
    • English
    • Español
    • Français
    • Italiano
    • Português
    • 日本語
    • 中文
  • Veolia 其他站点
    • Veolia
    • Veolia Foundation
    • Veolia Water Technologies
Elga Veolia
TOP

© 2017 ELGA Veolia